Elacestrant

CAS no.: 722533-56-4

Type: API

Usage: Breast cancer

Technical description
Elacestrant is a member of the class of tetralins that is 1,2,3,4-tetrahydronaphthalene which is substituted by hydroxy group at position 2 and by a 2-(ethylamino)-4-methoxyphenyl group at position 6R. It is a is an estrogen receptor degrader indicated for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. It has a role as an antineoplastic agent, an anti-estrogen and an estrogen receptor antagonist. It is a monomethoxybenzene, an organic hydroxy compound, a member of tetralins, a substituted aniline, a secondary amino compound and a tertiary amino compound.

IUPAC name: (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol

Molecular formula: C₃₀H₃₈N₂O₂

Molecular Weight: 458.6 g/mol

Class: An orally administered SERD (Selective Estrogen Receptor Degrader).

Synonyms: RAD-1901, RAD1901, ER-306323, ER306323.